Medical Guidance Systems

Medical Guidance Systems, founded in 2013, aims to operate in the USD 119.39 billion cancer immunotherapy market by providing new theragnostic opportunities for patients who have been diagnosed with poor prognosis cancers ; >500,000 patients in the US each year.